Schubert & Co’s Autoliv ALV Stock Holding History

Schubert & Co’s Portfolio ALV Stock Details ALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-58	Closed	-$5.42K	–	98
2023 Q1	$5.42K	Sell	58 -1	-2%	-$88	﹤0.01%	417
2022 Q4	$4.52K	Buy	59 +22	+59%	+$1.76K	﹤0.01%	474
2022 Q3	$2K	Sell	37 -13	-26%	-$1.01K	﹤0.01%	720
2022 Q2	$4K	Buy	50 +34	+213%	+$2.54K	﹤0.01%	407
2022 Q1	$1K	Buy	16 +1	+7%	+$92	﹤0.01%	552
2021 Q4	$2K	Buy	+15	New	+$1.47K	﹤0.01%	295

Other funds holding ALV

CCI

Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Schubert & Co's ALV Position: Q2 2023 in Review

Schubert & Co sold out of Autoliv (ALV) in Q2 2023, closing a stake of 58 shares — an estimated $5.42K sold.

Schubert & Co first reported a position in ALV in Q4 2021 and held it in 6 quarters. The position peaked at $5.42K in Q1 2023. 318 funds tracked by Wall St. Rank hold ALV as of Q2 2023.

Schubert & Co reported no remaining Autoliv position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 58 Autoliv shares in Q2 2023, an estimated $5.42K.
Schubert & Co first reported a position in Autoliv in Q4 2021 and held it in 6 quarters.
Schubert & Co's Autoliv position peaked at $5.42K in Q1 2023.
318 funds tracked by Wall St. Rank held Autoliv as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.